

**AUG 31, 2022**

# Patient Monitoring business at Medtronic partners with BioIntelliSense for exclusive U.S. hospital and hospital-to-home distribution rights of the BioButton multi-parameter wearable

Partnership enables Patient Monitoring business' commitment to transforming health monitoring by expanding access to continuous vital sign monitoring of patients from in-hospital to home

The BioButton® medical grade multi-parameter wearable measures up to 1,440 vital sign measurements per day, including skin temperature, respiratory rate at rest, heart rate at rest, and more.<sup>1</sup> This has the potential to help enable clinicians to better detect early signs of patient deterioration or, conversely, identify stable patients who may be candidates for earlier hospital discharge. The rechargeable BioButton has configurable acute and post-acute modes to continuously monitor patients as they transition from higher to lower acuity settings.

"Our vision is to empower clinicians and patients with actionable insights to personalize care – anytime, anywhere," said Frank Chan, president of the Patient Monitoring business, which is part of the Medical Surgical Portfolio at Medtronic. "Today, our solutions touch more than 100 million patients annually in hospitals. Through our collaboration with BioIntelliSense, we will expand our reach to help more patients in more places than ever before – supporting continuous connected care from hospital to home."

Since the pandemic, patient safety events resulting in death, permanent harm, or severe temporary harm have increased more than 30 percent.<sup>2</sup> Providers are faced with the unprecedented need to monitor higher-risk patients in lower acuity and home care settings. This is becoming increasingly difficult with staffing shortages projected to reach 3.2 million healthcare workers by 2026.<sup>3</sup>

"In partnership with Medtronic, we are poised to accelerate continuous connected care models that offer a new level of clinical surveillance and workflow efficiencies for hospitals that are challenged in today's environment of growing workforce shortages and cost of care management," said James Mault, MD, founder and CEO of BioIntelliSense. This advanced remote physiologic monitoring simplifies care delivery to facilitate personalized patient care, clinical workflow automation and proactive clinical interventions."



### **About the Patient Monitoring business at Medtronic**

The Patient Monitoring business is committed to transforming the future of health monitoring. Our vision is to empower clinicians and patients with actionable insights to personalize care – anytime, anywhere. Our market-leading technologies including Nellcor™ pulse oximetry, Microstream™ capnography, BIS™ brain monitoring, and INVOS™ regional oximetry are always on watch, helping clinicians keep patients safe. [Medtronic.com](https://www.Medtronic.com)

### **About Medtronic**

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission – to alleviate pain, restore health, and extend life – unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit [www.Medtronic.com](https://www.Medtronic.com) and follow [@Medtronic](https://twitter.com/Medtronic) on Twitter and [LinkedIn](https://www.linkedin.com/company/medtronic).

### **About BioIntelliSense**

BioIntelliSense is ushering in a new era of continuous health monitoring and clinical intelligence for Remote Patient Monitoring (RPM). Its medical-grade Data-as-a-Service (DaaS) platform seamlessly captures multi-parameter vital signs and physiological biometrics through an effortless patient experience. The medical-grade BioButton® devices make remote monitoring and early detection simple. Through the platform's advanced analytics, clinicians have access to high-resolution patient trending and alerting to enable medical grade remote care from in-hospital to at-home.

Learn how BioIntelliSense is redefining remote patient monitoring through medical-grade and cost-effective data services or visit our website at [BioIntelliSense.com](https://www.biointellisense.com). Follow BioIntelliSense on [Twitter](#) and [LinkedIn](#) for the latest news and information.

#### **Contacts:**

##### Medtronic

Tammy Hudson  
Public Relations  
+1-678-488-5337

Ryan Weispfenning  
Investor Relations  
+1-763-505-4626

##### BioIntelliSense

Eric Schudiske  
[eric@s2spr.com](mailto:eric@s2spr.com)

#### References:

1. Wellness parameters
2. *Joint Commission. Sentinel events reviewed by year, by source. Jan 2005 to Dec 2021.*
3. AHA. <https://www.aha.org/fact-sheets/2021-11-01-data-brief-health-care-workforce-challenges-threaten-hospitals-ability-care>

<https://news.medtronic.com/Patient-Monitoring-business-at-Medtronic-partners-with-BioIntelliSense-for-exclusive-U-S-hospital-and-hospital-to-home-distribution-rights-of-the-BioButton-multi-parameter-wearable>